---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-028620"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:28:38.781928+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals Approves CEO Compensation Adjustments Including Incentive Payouts and Salary Increase

## Summary
- CEO Erez Aminov received a 2025 short-term incentive payout of $400,000 for operational and financing achievements.
- Contingent milestone payout of $150,000 approved for future FDA acceptance of the Telomir-1 IND submission.
- Transaction advisory award of 3% of the total TELI acquisition value granted for leadership in negotiating the potential acquisition.
- Base salary adjusted to $500,000 effective January 1, 2026, based on external benchmarking.

## SEC filing metadata
- accession: 0001493152-25-028620
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315225028620/0001493152-25-028620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315225028620/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-028620
- JSON: https://secwatch.observer/filing/0001493152-25-028620.json
- Plain text: https://secwatch.observer/filing/0001493152-25-028620.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.